$CRSP
CRISPR Therapeutics AG

2018 Q3 Form 10-Q Financial Statement

#000156459018028026 Filed on November 07, 2018

View on sec.gov

Income Statement

Concept 2018 Q3 2017 Q3
Revenue $563.0K $2.387M
YoY Change -76.41% 54.1%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $10.20M $8.100M
YoY Change 25.93% 97.56%
% of Gross Profit
Research & Development $39.80M $17.80M
YoY Change 123.6% 47.69%
% of Gross Profit
Depreciation & Amortization $800.0K $800.0K
YoY Change 0.0% 300.0%
% of Gross Profit
Operating Expenses $50.00M $25.96M
YoY Change 92.61% 60.63%
Operating Profit -$49.43M -$23.57M
YoY Change 109.72% 61.33%
Interest Expense -$1.000M -$400.0K
YoY Change 150.0% 39900.0%
% of Operating Profit
Other Income/Expense, Net -$1.142M -$100.0K
YoY Change 1042.0% 31.58%
Pretax Income -$50.57M -$24.00M
YoY Change 110.73% 63.42%
Income Tax $100.0K $707.0K
% Of Pretax Income
Net Earnings -$50.71M -$24.71M
YoY Change 105.25% 68.3%
Net Earnings / Revenue -9007.28% -1035.06%
Basic Earnings Per Share -$1.07 -$0.62
Diluted Earnings Per Share -$1.07 -$0.62
COMMON SHARES
Basic Shares Outstanding 47.39M 40.09M
Diluted Shares Outstanding 47.39M 40.09M

Balance Sheet

Concept 2018 Q3 2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $487.3M $253.5M
YoY Change 92.23% 10.89%
Cash & Equivalents $487.3M $253.5M
Short-Term Investments
Other Short-Term Assets $8.800M $1.900M
YoY Change 363.16% 111.11%
Inventory
Prepaid Expenses
Receivables $552.0K $3.200M
Other Receivables $0.00 $0.00
Total Short-Term Assets $496.7M $258.6M
YoY Change 92.07% 11.63%
LONG-TERM ASSETS
Property, Plant & Equipment $18.10M $19.60M
YoY Change -7.67% 407.51%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00
YoY Change -100.0%
Other Assets $650.0K $3.800M
YoY Change -82.89% -2.26%
Total Long-Term Assets $22.22M $23.70M
YoY Change -6.27% -49.58%
TOTAL ASSETS
Total Short-Term Assets $496.7M $258.6M
Total Long-Term Assets $22.22M $23.70M
Total Assets $518.9M $282.3M
YoY Change 83.81% 1.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.221M $2.100M
YoY Change 148.62% 8.08%
Accrued Expenses $25.84M $8.500M
YoY Change 203.94% -31.46%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $32.28M $12.10M
YoY Change 166.76% -84.51%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $273.0K $91.20M
YoY Change -99.7% 15788.5%
Total Long-Term Liabilities $273.0K $91.20M
YoY Change -99.7% 15788.5%
TOTAL LIABILITIES
Total Short-Term Liabilities $32.28M $12.10M
Total Long-Term Liabilities $273.0K $91.20M
Total Liabilities $101.6M $103.4M
YoY Change -1.75% -33.56%
SHAREHOLDERS EQUITY
Retained Earnings -$244.0M
YoY Change
Common Stock $661.4M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost) $57.00K
YoY Change
Treasury Stock Shares $307.9K
Shareholders Equity $417.3M $179.0M
YoY Change
Total Liabilities & Shareholders Equity $518.9M $282.3M
YoY Change 83.81% 1.31%

Cashflow Statement

Concept 2018 Q3 2017 Q3
OPERATING ACTIVITIES
Net Income -$50.71M -$24.71M
YoY Change 105.25% 68.3%
Depreciation, Depletion And Amortization $800.0K $800.0K
YoY Change 0.0% 300.0%
Cash From Operating Activities -$19.97M -$15.87M
YoY Change 25.83% 29.34%
INVESTING ACTIVITIES
Capital Expenditures -$690.0K -$2.990M
YoY Change -76.92% 98.01%
Acquisitions
YoY Change
Other Investing Activities -$500.0K
YoY Change
Cash From Investing Activities -$690.0K -$3.490M
YoY Change -80.23% 131.13%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 188.2M 600.0K
YoY Change 31270.0% -113.39%
NET CHANGE
Cash From Operating Activities -19.97M -15.87M
Cash From Investing Activities -690.0K -3.490M
Cash From Financing Activities 188.2M 600.0K
Net Change In Cash 167.6M -18.76M
YoY Change -993.18% 2.74%
FREE CASH FLOW
Cash From Operating Activities -$19.97M -$15.87M
Capital Expenditures -$690.0K -$2.990M
Free Cash Flow -$19.28M -$12.88M
YoY Change 49.69% 19.7%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
3165000
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2018Q3 us-gaap Cash
Cash
487295000
CY2018Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
659776000
CY2017Q4 crsp Contract With Customer Liability Noncurrent With Related Parties
ContractWithCustomerLiabilityNoncurrentWithRelatedParties
91000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-50711000
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.07
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
47391988
CY2018Q3 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
443000
CY2018Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9067000
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2018Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
552000
CY2018Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8841000
CY2018Q3 us-gaap Assets Current
AssetsCurrent
496688000
CY2018Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
18097000
CY2018Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
303000
CY2018Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
650000
CY2018Q3 us-gaap Assets
Assets
518903000
CY2018Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
5221000
CY2018Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
25835000
CY2018Q3 us-gaap Taxes Payable Current
TaxesPayableCurrent
24000
CY2018Q3 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
1027000
CY2018Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
171000
CY2018Q3 us-gaap Liabilities Current
LiabilitiesCurrent
32278000
CY2018Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
57806000
CY2017Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
56928000
CY2018Q3 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
11232000
CY2018Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
273000
CY2018Q3 us-gaap Liabilities
Liabilities
101589000
CY2018Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q3 us-gaap Common Stock Value
CommonStockValue
1575000
CY2018Q3 us-gaap Treasury Stock Value
TreasuryStockValue
57000
CY2018Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-243979000
CY2018Q3 us-gaap Revenues
Revenues
563000
CY2018Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1000
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
417314000
CY2018Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
518903000
CY2018Q3 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
457000
CY2018Q3 crsp Prepaid Expense And Other Assets Related Parties Current
PrepaidExpenseAndOtherAssetsRelatedPartiesCurrent
52000
CY2018Q3 crsp Accrued Expenses Related Parties Current
AccruedExpensesRelatedPartiesCurrent
234000
CY2018Q3 crsp Contract With Customer Liability Noncurrent With Related Parties
ContractWithCustomerLiabilityNoncurrentWithRelatedParties
0
CY2018Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.03
CY2018Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
51893132
CY2018Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
51862415
CY2018Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
51554479
CY2018Q3 crsp Common Stock Conditional Capital
CommonStockConditionalCapital
19520914
CY2018Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
307936
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-15000
CY2018Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-50717000
CY2017Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24699000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-117406000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-117072000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
319000
CY2017Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
8000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3357000
CY2017Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-24000000
CY2018Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
137000
CY2017Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
707000
CY2018Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-6000
us-gaap Operating Income Loss
OperatingIncomeLoss
-65620000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-1310000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-238000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1548000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-67168000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1330000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-24707000
us-gaap Net Income Loss
NetIncomeLoss
-117391000
us-gaap Net Income Loss
NetIncomeLoss
-68498000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
38000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-68460000
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.62
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.51
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.72
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
40088718
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
46709388
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
39904863
CY2017Q3 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
1249000
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
2406000
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
3888000
CY2018Q3 crsp Research And Development Expense From Related Party
ResearchAndDevelopmentExpenseFromRelatedParty
418000
CY2017Q3 crsp Research And Development Expense From Related Party
ResearchAndDevelopmentExpenseFromRelatedParty
1208000
crsp Research And Development Expense From Related Party
ResearchAndDevelopmentExpenseFromRelatedParty
2770000
crsp Research And Development Expense From Related Party
ResearchAndDevelopmentExpenseFromRelatedParty
3699000
us-gaap Profit Loss
ProfitLoss
-117391000
us-gaap Profit Loss
ProfitLoss
-68498000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2574000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2218000
us-gaap Share Based Compensation
ShareBasedCompensation
21960000
us-gaap Share Based Compensation
ShareBasedCompensation
11894000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
9000
crsp Income Loss From Equity Method Investments And Investment Compensation Expense
IncomeLossFromEquityMethodInvestmentsAndInvestmentCompensationExpense
-3256000
crsp Income Loss From Equity Method Investments And Investment Compensation Expense
IncomeLossFromEquityMethodInvestmentsAndInvestmentCompensationExpense
-1310000
crsp Expense Related To Collaboration Agreement
ExpenseRelatedToCollaborationAgreement
15109000
us-gaap Other Noncash Income
OtherNoncashIncome
169000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2074000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
54000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2502000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
304000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
7982000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2979000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-270000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
2043000
crsp Increase Decrease In Deferred Rent Payable
IncreaseDecreaseInDeferredRentPayable
-528000
crsp Increase Decrease In Deferred Rent Payable
IncreaseDecreaseInDeferredRentPayable
-903000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
38000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
31000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-67867000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-55251000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1773000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7609000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
500000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1773000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-8109000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
309019000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
8241000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1324000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
57000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
317203000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1324000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-15000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
39000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
247548000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-61997000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
242912000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
318670000
CY2018Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
490460000
CY2017Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
256673000
crsp Costs For Supplemental Offering In Accounts Payable And Accrued Expenses
CostsForSupplementalOfferingInAccountsPayableAndAccruedExpenses
1980000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
118000
crsp Cost Sharing Expenses Incurred
CostSharingExpensesIncurred
1100000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
25216000
CY2017Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5227000
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2013-10-28
dei Entity Incorporation State Country Name
EntityIncorporationStateCountryName
Basel, Switzerland
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6877463
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5842856
CY2018Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
24541000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
22768000
CY2018Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6444000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3911000
CY2018Q3 us-gaap Depreciation
Depreciation
800000
us-gaap Depreciation
Depreciation
2500000
CY2017Q3 us-gaap Depreciation
Depreciation
800000
us-gaap Depreciation
Depreciation
2200000
CY2018Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5353000
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5550000
CY2018Q3 crsp Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
6830000
CY2017Q4 crsp Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
2285000
CY2018Q3 crsp Accrued License Fees Current
AccruedLicenseFeesCurrent
144000
CY2017Q4 crsp Accrued License Fees Current
AccruedLicenseFeesCurrent
609000
CY2018Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2397000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2176000
CY2018Q3 crsp Accrued Intellectual Property Costs Current
AccruedIntellectualPropertyCostsCurrent
1505000
CY2017Q4 crsp Accrued Intellectual Property Costs Current
AccruedIntellectualPropertyCostsCurrent
500000
CY2018Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1997000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
241000
CY2018Q3 crsp Cost Sharing Expenses Incurred
CostSharingExpensesIncurred
500000
crsp Cost Sharing Expenses Incurred
CostSharingExpensesIncurred
1600000
CY2017Q3 crsp Cost Sharing Expenses Incurred
CostSharingExpensesIncurred
100000
crsp Cost Sharing Expenses Accrued
CostSharingExpensesAccrued
1400000
CY2017 crsp Cost Sharing Expenses Accrued
CostSharingExpensesAccrued
400000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13204000
CY2018Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
90600000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y1M6D
CY2016Q4 us-gaap Equity Method Investments
EquityMethodInvestments
36500000
CY2016 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-36500000
CY2018Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
19520914
CY2017Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
16419632
crsp Joint Venture Agreement Date
JointVentureAgreementDate
2015-12-19
CY2016Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
35000000
CY2018Q3 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures Fair Value Disclosure
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure
106300000
CY2016 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
79100000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
366401
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
89000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
236244
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
40273
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
178884
CY2018Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.003
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.003
CY2017Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.029
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.020

Files In Submission

Name View Source Status
0001564590-18-028026-index-headers.html Edgar Link pending
0001564590-18-028026-index.html Edgar Link pending
0001564590-18-028026.txt Edgar Link pending
0001564590-18-028026-xbrl.zip Edgar Link pending
crsp-10q_20180930.htm Edgar Link pending
crsp-20180930.xml Edgar Link completed
crsp-20180930.xsd Edgar Link pending
crsp-20180930_cal.xml Edgar Link unprocessable
crsp-20180930_def.xml Edgar Link unprocessable
crsp-20180930_lab.xml Edgar Link unprocessable
crsp-20180930_pre.xml Edgar Link unprocessable
crsp-ex101_445.htm Edgar Link pending
crsp-ex311_8.htm Edgar Link pending
crsp-ex312_6.htm Edgar Link pending
crsp-ex31_405.htm Edgar Link pending
crsp-ex321_7.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gleawceockkv000001.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending